Overview

Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis

Status:
NOT_YET_RECRUITING

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

This was a multicenter, randomized, open label, non inferiority clinical study. It consisted of a 24-week treatment period (0-24 weeks) and a 24-week extension period (25-48 weeks). About 160 patients which had received Recombinant human erythropoietin (rHuEPO) or Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) treatment were randomized in a 1:1 ratio to receive Pegmolesatide with different administration regimens.

Phase:

PHASE4

Details

Lead Sponsor:

The First Affiliated Hospital of Dalian Medical University

Collaborator:

Jiangsu Hansoh Pharmaceutical Co., Ltd.